Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 27, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: September 23, 2005
- Previous Holding: 18,372,178 ADRs
- New Holding: 18,406,628 ADRs
- Average Price: $49.76
The increase resulted from a movement in the fund. The Plan is a discretionary fund for current and former employees. Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses the notification of the share transaction under Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of ADRs held by the US Retirement Savings Plan post-transaction (18,406,628).
- Confirm the potential interest of Directors Dr. J P Garnier and Dr. T Yamada in the fund's holdings.
- Note that this filing does not contain financial performance data for the period.